The company has a robust pipeline of antibiotics, including EMROK, EMROK O, and MIQNAF, targeting critical infections. The company recently announced that its oral antibiotic Miqnaf (Nafithromycin) ...

Wockhardt Ltd. expects around Rs 400 crore revenue from its new generation oral antibiotic, Nafithromycin, in the next two to three years, according to Founder and Chairman Kabil Kharoiwala. The drug, ...

Shares of Wockhardt are higher by 5% on January 3 after Indian drug regulator approved oral antibiotic for the treatment of Pneumonia, the company informed in an exchange filing. Central Drugs ...

The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults ...

Total business grows 16.9% to Rs 5.08 lakh crore Vs Rs 4.34 lakh crore Gross advances increase 21.2% to Rs 2.29 lakh crore Vs Rs 1.89 lakh crore ...